Combination Cisplatin and Carboplatin in Advanced Squamous Cell Carcinoma of the Head and Neck

References

• Kish J. A., Weaver A., Jacobs J., Cummings G., Al-Sarraj M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819–1824
   PubMed Web of Science ®Google Scholar
• Rowland K. M., Taylor S. G., O'Donnell M. R., Spiers A. S., DeConti R. C., Showel J. Cisplatin and 5-FU infusion chemotherapy in advanced recurrent cancer of the head and neck: An Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 1986; 70: 461–464
   PubMedGoogle Scholar
• Creagen E., Ingle J., O'Fallon J. R. A phase II study of cisdiamine-dichloroplatinum and 5-fluorouracil in advanced upper aerodigestive neoplasms. Head Neck Surg 1984; 6: 1020–1023
   PubMedGoogle Scholar
• Choksi A. J., Hong W. K., Dimery I. W., James P., Guillamondequi D. M., Byers R. M. Continuous cisplatin (24-hour) and 5-fluorouracil (120-hour) infusion in recurrent head and neck squamous cell carcinoma. Cancer 1988; 61: 909–912
   PubMed Web of Science ®Google Scholar
• Wittes R., Heller K., Randolph V., Howard J., Vallejo A., Fair H. Cis-dichlorodiammineplatinum (Il)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep 1979; 63: 1533–1538
   PubMedGoogle Scholar
• Panettiere F. J., Lehane D., Fletcher W. S., Stephens R., Rivkins S. R., McCracken J. D. Cisplatin therapy of previously treated head and neck cancer: The Southwest Oncology Group's two-dose-per-month outpatient regimen. Med Pediatr Oncol 1980; 8: 221–225
   PubMedGoogle Scholar
• Jacobs C., Bertino J. R., Goffinet D. R., Fee W. E., Goode R. L. 24-Hour infusion of cis-platinum in head and neck cancers. Cancer 1978; 42: 2135–2140
   PubMed Web of Science ®Google Scholar
• Jacobs C., Meyers F., Hendrickson C., Kohler M., Carter S. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A Northern California Oncology Group study. Cancer 1983; 52: 1563–1569
   PubMed Web of Science ®Google Scholar
• Hong W. K., Schaefer S., Issel B., Cumings C., Luedke D., Bromer R. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer 1983; 52: 206–210
   PubMed Web of Science ®Google Scholar
• Sako K., Razack M. S., Kalnins I. Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum. Am J Surg 1978; 136: 529–533
   PubMed Web of Science ®Google Scholar
• Loehrer P. J., Einhorn L. H. Cisplatin. Ann Intern Med 1984; 100: 704–713
   PubMed Web of Science ®Google Scholar
• Eisenberger M., Hornedo J., Suva H., Donehower R., Spaulding M., Van Echo D. Carboplatin (NSC-241–240): An active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1986; 4: 1506–1509
   PubMed Web of Science ®Google Scholar
• De Andres B. L., Lopez P. A., Alba E., Sampedro F. Carboplatin, an active drug in advanced head and neck cancer. Cancer Treat Rep 1986; 70: 1173–1176
   PubMedGoogle Scholar
• Al-Sarraj M., Metch B., Kish J., Ensley J., Rinehart J. J., Schuller D. E. Platinum analogs in recurrent and advanced head and neck cancer: A Southwest Oncology Group and Wayne State University Study. Cancer Treat Rep 1987; 71: 723–726
   PubMedGoogle Scholar
• Evans B. D., Raju K. S., Calvert A. H., Harland S. J., Wiltshaw E. (cis-diammine-1,1-cyclobutane dicarboxylate platinum II): A new platinum analogue active in the treatment of advanced ovarian carcinoma. Cancer Treat Rep 1983; 67: 997–1000
   PubMedGoogle Scholar
• Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev 1985; 12(Suppl A)67–71, abstract
   PubMed Web of Science ®Google Scholar
• Hong R., Ohnuma T., Inoue S., Sun A. S., Holland J. F. Cisplatin and Carboplatin in combination. Proc Am Assoc Cancer Res 1985; 26: 260, abstract
   Web of Science ®Google Scholar
• Miller A., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214
   PubMed Web of Science ®Google Scholar
• Dimery I. W., Brooks B. J., Winn R., Martin T., Shirinian M., Hong W. K. Phase II trial of Carboplatin plus cisplatin in recurrent and advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1991; 9: 1939–1944
   PubMed Web of Science ®Google Scholar
• Ozols R. F., Corden B. J. High-dose cisplatin in hypertonic saline. Ann Intern Med 1984; 100: 19–24
   PubMed Web of Science ®Google Scholar
• Bruckner H. W., Wallach R., Cohen C. J., Deppe G., Kabakow B., Ratner L. High dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 1981; 12: 64–67
   PubMed Web of Science ®Google Scholar
• Hayes D. M., Cvitkovic E., Golbey R. B., Scheiner E., Helson L., Krakoff I. H. High dose cisplatinum diamminedichloride: Amelioriation of renaltoxiätyby mancitol diuresis. Cancer 1977; 39: 1372–1381
   PubMed Web of Science ®Google Scholar
• Trump D. L., Grem J. L., Tutsch K. D., Willson J. KV, Simon K. J., Alberti D., Storer B., Tormey D. C. Platinum analogue combination chemotherapy: Cisplatin and Carboplatin—A phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on Carboplatin excretion. J Clin Oncol 1987; 5: 1281–1289
   PubMed Web of Science ®Google Scholar
• Nitani H., Kobayashi K. Cisplatin/carboplatin therapy in non-small cell lung cancer. Oncology 1992; 49(Suppl 1)51–56
   PubMedGoogle Scholar
• Bertelsen K., Bastholt L. High-dose platinum chemotherapy in advanced ovarian cancer: A phase II study. Gynecol Oncol 1992; 44: 79–82
   PubMed Web of Science ®Google Scholar